Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical-stage gene-editing company developing therapies with its proprietary ARCUS platform, a compact, single-component nuclease system designed to make targeted DNA insertions, eliminations and excisions. Its wholly owned clinical programs include PBGENE-HBV, an in… From the company’s description.
Over the twelve months to Sep 30, 2026, Precision BioSciences, Inc. reported revenue of $45.04M, up 6353.0% from a year earlier, and a net loss of $38.55M. Its operating margin was −80.3%, and operations used $51.76M in cash. In fiscal 2025, it reported revenue of $34.26M, down 50.1% from fiscal 2024, and a net loss of $45.72M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Precision BioSciences, Inc. does
In the company’s own words
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical-stage gene-editing company developing therapies with its proprietary ARCUS platform, a compact, single-component nuclease system designed to make targeted DNA insertions, eliminations and excisions. Its wholly owned clinical programs include PBGENE-HBV, an in vivo therapy intended to eliminate hepatitis B viral DNA, and PBGENE-DMD, designed to remove part of the dystrophin gene in Duchenne muscular dystrophy; development of its mitochondrial disease program is paused. The company also partners with iECURE on an ARCUS-based gene-insertion therapy for ornithine transcarbamylase deficiency. Precision licenses ARCUS and related technology to partners and holds licenses for other therapeutic applications. It operates as a gene-editing business, with no reportable operating segments described in the provided business overview. As of December 31, 2025, the company had 19 full-time employees with Ph.D. or M.D. degrees. Its website is www.precisionbiosciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- May
- CIK
- 1357874
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Precision BioSciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Precision BioSciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Precision BioSciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Precision BioSciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Precision BioSciences, Inc.'s last four quarterly filings that the numbers alone won't show?”